July 29 (Reuters) - Neuren Pharmaceuticals Ltd NEU.AX :
* Orphan drug designation for trofinetide in both rett syndrome and fragile x syndrome recommended by European medicines agency
* Enrolment completed in fragile x phase 2 clinical trial; top-line results expected in December 2015
* Says anticipates that the European commission will provide formal confirmation of these designations in August 2015
* Says to propose to FDA a design for a single phase 3 clinical trial to support a new drug application for rett syndrome
* Source text for Eikon ID:nASX68WyKV